Description

Pomalid (Pomalidomide)

Introduction

Pomalid (generic name: pomalidomide) is an immunomodulatory medication primarily used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. It belongs to a class of drugs known as immunomodulatory agents and is structurally related to thalidomide and lenalidomide.

Mechanism of Action

Pomalidomide works through multiple mechanisms to help control cancer growth. It enhances the body’s immune response against cancer cells, inhibits the growth and survival of malignant plasma cells, and reduces the formation of new blood vessels that tumors need for growth. These combined effects help slow disease progression and improve patient outcomes.

Indications

Pomalidomide is commonly prescribed for adult patients with relapsed or refractory multiple myeloma who have previously received other treatments. It is often used in combination with dexamethasone and may be combined with additional therapies depending on the patient’s condition and treatment history.

Dosage and Administration

The dosage of pomalidomide is determined by a healthcare professional based on the patient’s medical condition, response to treatment, and overall health status. The medication is typically administered orally in capsule form and should be taken exactly as prescribed. Patients should not open, crush, or chew the capsules.

Common Side Effects

Common side effects associated with pomalidomide include:

• Fatigue
• Weakness
• Constipation
• Diarrhea
• Nausea
• Shortness of breath
• Fever
• Back pain
• Decreased appetite

Additionally, pomalidomide may cause low blood cell counts, increasing the risk of infections, anemia, and bleeding complications.

Warnings and Precautions

Pomalidomide carries important safety warnings, including:

• Risk of severe birth defects if used during pregnancy.
• Increased risk of blood clots.
• Potential for serious infections due to reduced white blood cell counts.
• Risk of liver toxicity and other serious adverse reactions.

Women who are pregnant or may become pregnant should not use pomalidomide. Effective contraception is required during treatment according to prescribing guidelines.

Monitoring

Patients receiving pomalidomide require regular monitoring, including:

• Complete blood count (CBC)
• Liver function tests
• Assessment for signs of infection
• Monitoring for thromboembolic events

Conclusion

Pomalidomide is an important treatment option for patients with relapsed or refractory multiple myeloma. By modulating immune function and directly affecting cancer cell survival, it can help manage disease progression and improve treatment outcomes. Due to its potential risks and side effects, treatment should always be supervised by qualified healthcare professionals.